Identifying Biomarkers for Dasatinib in Prostate Cancer
Author Information
Author(s): Wang Xi-De, Reeves Karen, Luo Feng R, Xu Li-An, Lee Francis, Clark Edwin, Huang Fei
Primary Institution: Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey, USA
Hypothesis
Can gene expression profiling identify predictive and surrogate molecular markers for dasatinib efficacy in prostate cancer?
Conclusion
The study identified five biomarkers associated with sensitivity to dasatinib, providing a basis for patient stratification in clinical trials.
Supporting Evidence
- 174 genes were identified as candidate efficacy predictive markers.
- Basal type cell lines with high CK5 expression are sensitive to dasatinib.
- uPA expression was down-regulated by dasatinib treatment, correlating with sensitivity.
Takeaway
Researchers looked at how certain genes in prostate cancer cells respond to a drug called dasatinib to find out which patients might benefit from it.
Methodology
Gene expression profiling was used to identify genes correlated with dasatinib sensitivity in prostate cancer cell lines.
Limitations
The study is based on preclinical models and may not fully represent patient responses.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website